Lv0
0 积分 2025-03-24 加入
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophagealjunction adenocarcinoma: a randomized, double-blind, phase 3 trial
1天前
待确认
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer The GEMSTONE-303 Randomized Clinical Trial
1天前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
1天前
已完结
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer The ORIENT-16 Randomized Clinical Trial
1天前
已完结
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
1天前
已完结
皖公网安备34019202002308
